Hematology

Latest News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

By Jared Kaltwasser

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS

By Mary Caffrey
Caspian Oliai, MD, MS

April 11th 2025

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

By Jared Kaltwasser

April 10th 2025

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com

Immune Microenvironment a Key Target in CLL

By Jared Kaltwasser

April 8th 2025

Health equity concept | image credit: VectorMine - stock.adobe.com

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

By Kyle Munz
Ajai Chari, MD

April 7th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

More News

Vitamin D Deficiency Associated With Worse Hospital Outcomes in Pediatric Patients With Sickle Cell Disease

March 11th 2020

Vitamin D Deficiency Associated With Worse Hospital Outcomes in Pediatric Patients With Sickle Cell Disease

Matthew Gavidia

In children and adolescents with sickle cell disease, those who lacked ample vitamin D were hospitalized more often, had longer hospital stays, and made more frequent visits to the emergency department, according to study findings.

What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab

March 9th 2020

What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab

A year after being only the second person to be cured of HIV, the “London Patient” revealed his identity; BMS announced today that its combination therapy for multiple myeloma—elotuzumab, lenalidomide, and dexamethasone—failed its primary endpoint of progression-free survival in its phase 3 ELOQUENT-1 trial; Biocon and Mylan N.V. announced that the FDA accepted their biologics license application (BLA) for MYL-14020, a proposed biosimilar to bevacizumab (Avastin), for review.

$FDA Approves Isatuximab-irfc for Treatment of Relapsed Refractory Multiple Myeloma$

March 5th 2020

FDA Approves Isatuximab-irfc for Treatment of Relapsed Refractory Multiple Myeloma

Matthew Gavidia

Isatuximab-irfc, sold as Sarclisa, in combination with pomalidomide and dexamethasone, was approved this week by the FDA for the treatment of adults with relapsed refractory multiple myeloma who have received at least 2 prior therapies.

Dr Adam Olszewski on Research Still Needed on Palliative Care Services in Blood Cancers

March 3rd 2020

Dr Adam Olszewski on Research Still Needed on Palliative Care Services in Blood Cancers

More data is needed to get wider acceptance of the use of palliative care services for patients with blood cancers, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.

Higher Microbiota Diversity in Hematologic Cancer Treatment Could Lower Mortality Risk, Study Finds

February 27th 2020

Higher Microbiota Diversity in Hematologic Cancer Treatment Could Lower Mortality Risk, Study Finds

Matthew Gavidia

For patients undergoing allogeneic hematopoietic cell transplantation, higher diversity of intestinal microbiota at the time of neutrophil engraftment was linked with lower mortality, according to study findings published today.

Multiple Myeloma Rates in China Align With Other Asian Countries

February 23rd 2020

Multiple Myeloma Rates in China Align With Other Asian Countries

Jared Kaltwasser

In a major study of a Chinese medical insurance database, investigators found the prevalence and incidence of the disease in China is similar to those of its neighbors, but lower than countries in the West.

Dr C. Patrick Carroll on Biases Impacting African Americans With Sickle Cell Disease and Pain

February 19th 2020

Dr C. Patrick Carroll on Biases Impacting African Americans With Sickle Cell Disease and Pain

Patients with sickle cell disease already face suspicion and biases based on their need for opioids, and African American patients also face additional racial biases, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.

Imaging CAR T Cells Will Assist Doctors' Treatment Strategies, Says Dr Reona Sakemura

February 18th 2020

Imaging CAR T Cells Will Assist Doctors' Treatment Strategies, Says Dr Reona Sakemura

Predicting T-cell toxicity is a key factor when it comes to successfully using CAR T-cell therapy, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.

Sickle Cell Trait, Disease Linked With Faster Kidney Function Decline in African American Patients

February 18th 2020

Sickle Cell Trait, Disease Linked With Faster Kidney Function Decline in African American Patients

Matthew Gavidia

Sickle-cell trait (SCT) and disease (SCD) among African American patients were associated with faster kidney function decline, with SCD contributing to a more rapid decline, according to study findings.

Scientists Unveil New Target to Stop Bortezomib Resistance in Patients With Multiple Myeloma

February 16th 2020

Scientists Unveil New Target to Stop Bortezomib Resistance in Patients With Multiple Myeloma

Jared Kaltwasser

Primary and acquired resistance to bortezomib can increase recurrence rates in patients with multiple myeloma. A new strategy could help reduce resistance.

Dr Adam Olszewski: Early Palliative Care Is Important and Beneficial for Patients With Blood Cancers

February 15th 2020

Dr Adam Olszewski: Early Palliative Care Is Important and Beneficial for Patients With Blood Cancers

Evidence is showing that early palliative care can be beneficial for patients with blood cancers, who receive very intense treatments that impact quality of life, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.

Early Study of Bendamustine, Carfilzomib Shows Encouraging Results

February 14th 2020

Early Study of Bendamustine, Carfilzomib Shows Encouraging Results

Researchers describe results of carfilizomib and bendamustine in a phase 1/2 study.

$Daratumumab-Based Combination Regimen Submitted for FDA Approval in Relapsed/Refractory Multiple Myeloma$

February 12th 2020

Daratumumab-Based Combination Regimen Submitted for FDA Approval in Relapsed/Refractory Multiple Myeloma

Matthew Gavidia

Based on positive data from the phase 3 CANDOR study presented at the 2019 American Society of Hematology Annual Meeting, Janssen announced yesterday the submission of a supplemental biologics license application to the FDA seeking approval of daratumumab in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.

Dr Reona Sakemura Explains Why Certain Cancers Are More Susceptible to CAR T-Cell Therapy

February 11th 2020

Dr Reona Sakemura Explains Why Certain Cancers Are More Susceptible to CAR T-Cell Therapy

Bone marrow derived cancer-associated fibroblasts promote tumor progression which can alter a treatment's course, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.

Dr C. Patrick Carroll on Barriers to Accessing Nonpharmacologic Treatments to SDC-Related Pain

February 8th 2020

Dr C. Patrick Carroll on Barriers to Accessing Nonpharmacologic Treatments to SDC-Related Pain

There is not a lot of evidence on how well nonpharmacologic treatments work to treat sickle cell disease–related pain, and it can be difficult to get people access to these treatments, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.

Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies

February 4th 2020

Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies

Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.

Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma

January 31st 2020

Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma

Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib, a next-generation PI, treats RRMM as both a monotherapy and in combination; and ixazomib, the first oral PI, treats RRMM in combination. PIs work by preventing the proteasomes in cancerous plasma cells from “recycling” what is essentially garbage protein.

Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell Disease–Related Pain

January 30th 2020

Dr C. Patrick Carroll on Caution Using Opioids to Treat Sickle Cell Disease–Related Pain

Patients had never been particularly enthusiastic about using opioids to treat their pain related to sickle cell disease, but they are more cautious now, especially as they are often meet with suspicion of addiction, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.

Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease

January 29th 2020

Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease

Managing people with sickle cell disease and complex chronic pain is difficult and requires some trial and error, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.

ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia

January 25th 2020

ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia

Matthew Gavidia

The Institute for Clinical and Economic Review (ICER) published a draft evidence report on crizanlizumab (Adakveo), voxelotor (Oxbryta), and L-glutamine (Endari) for sickle cell disease, as well as a draft scoping document on valoctocogene roxaparvovec, an investigational gene therapy, and emicizumab (Helimbra) for hemophilia.

January 22nd 2020

Managing Vaso-Occlusive Crisis in Sickle Cell Disease: A Look at the Clinical and Economic Burden

https://www.pharmacytimes.org/on-demand/managing-vasoocclusive-crisis-in-sickle-cell-disease-a-look-at-the-clinical-and-economic-burden

January 21st 2020

Biosimilars at ASH 2019: Data on Truxima and Competitors for Eculizumab

Results for Truxima, recently launched in the United States, and complement inhibitors were presented at the 61st American Society of Hematology Annual Meeting and Exposition.

January 21st 2020

ASH 2019: Patient-Reported Outcomes, From MOST to FDA Clinical Reviews

Symptom burden, functional ability, and quality of life are necessary considerations when treating hematologic malignancies in older patients.

January 21st 2020

ASH 2019: Real-World Evidence and Cost of Care

Maggie L. Shaw Mary Caffrey

Reviews of apixaban in active cancer, Medicare costs after CAR T-cell therapy, and the need for financial assistance for novel therapies.

January 20th 2020

CAR T-Cell Therapy and Beyond: UCART 19 and Anti-BCMA Therapy

A pair of interviews on investigational therapies whose sponsors reported updates at the 61st American Society of Hematology Annual Meeting and Exposition: UCART19 from Servier and a revamped anti-BCMA therapy ide-cel from bluebird bio.

January 20th 2020

CAR T-Cell Therapy and Beyond: Off-the-Shelf Therapies Among Innovations at ASH 2019

Coverage from the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, featured results for allogeneic or "off the shelf" CAR T-cell treatments and bispecific antibodies.

PBSC Mobilization Yields Sufficient CD34+ Cell Counts in Patients With MM and Lymphoma, Study Finds

January 19th 2020

PBSC Mobilization Yields Sufficient CD34+ Cell Counts in Patients With MM and Lymphoma, Study Finds

Alison Rodriguez

A study identifying the different factors influencing peripheral blood hematopoietic stem cell (PBSC) mobilization and collection in multiple myeloma (MM) and lymphoma cases determined that PBSC mobilization yielded sufficient CD34+ cell counts in both patients with MM and lymphoma, but the failure rates were high.

Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trial

January 17th 2020

Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trial

Sickle cell disease is the most common red blood cell disorder in the United States, having been diagnosed in approximately 100,000 African Americans alone. The lack of oxygen from sickle cell buildup can lead to acute pain crises, joint and organ damage, stroke, and reduced life expectancy.

Managing Sickle Cell Disease: Innovations, Limitations Within Evolving Standards of Care

January 16th 2020

Managing Sickle Cell Disease: Innovations, Limitations Within Evolving Standards of Care

Matthew Gavidia

In the evolving treatment landscape for sickle cell disease, current standards of treatment involve 4 drugs that have been FDA approved, with further innovations and limitations adding to the paradigm of care.

Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis

January 15th 2020

Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis

Research has shown that fedratinib favorably impacts health-related quality of life for patients with myelofibrosis across the board, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.

...

6 7 8 9 10 11 12 13 14

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions